Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | AR | P10275 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20964616 | 0.91 | ALDH1A1 (0.73) | SMN1; SMN2TSHRLMNAALDH1A1KMT2A | |
| SCHEMBL20964944 | 0.86 | TSHR (0.77) | SMN1; SMN2TSHRLMNAALDH1A1KMT2A | |
| SCHEMBL20964719 | 0.86 | SMN1; SMN2 (0.77) | SMN1; SMN2TSHRLMNAALDH1A1KMT2A | |
| SCHEMBL19747273 | 0.85 | SMN1; SMN2 (0.71) | SMN1; SMN2TSHRLMNAKMT2AMEN1 | |
| SCHEMBL20964733 | 0.85 | SMN1; SMN2 (0.75) | SMN1; SMN2TSHRLMNAALDH1A1KMT2A | |
| SCHEMBL20964690 | 0.83 | ALDH1A1 (0.79) | SMN1; SMN2TSHRLMNAALDH1A1KMT2A | |
| SCHEMBL19745442 | 0.83 | LMNA (1.00) | SMN1; SMN2TSHRLMNAALDH1A1KMT2A | |
| SCHEMBL20964654 | 0.82 | ALDH1A1 (0.76) | SMN1; SMN2TSHRLMNAALDH1A1KMT2A | |
| SCHEMBL20964600 | 0.81 | TSHR (0.56) | SMN1; SMN2TSHRLMNAALDH1A1KMT2A | |
| SCHEMBL20964658 | 0.80 | LMNA (0.82) | SMN1; SMN2TSHRLMNAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190127361-A1 | Therapeutic Compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127361-A1 | Therapeutic Compounds | SDHA, SLC10A1, SERPINC1 | SMN1; SMN2 263/4885TSHR 3423/4885LMNA 1413/4885 |
| US-10851096-B2 | Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents | SERPINC1, F12, RPL35 | SMN1; SMN2 2477/4885TSHR 2794/4885LMNA 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.